Sublingual Apomorphine (Kynmobi) for Parkinson ' s Disease

Date: October 19, 2020
Issue #: 
1609Summary: 
The FDA has approved a sublingual fi lm formulation
of the nonergot dopamine agonist apomorphine
(Kynmobi– Sunovion) for acute, intermittent treatment
of " off " episodes in patients with Parkinson ' s disease
(PD). A subcutaneous formulation of apomorphine(Apokyn) has been available for years for the same
indication in patients with advanced PD.

Source: The Medical Letter - October 9, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research